Afatinib in combination with GEMOX chemotherapy as the adjuvant treatment in patients with ErbB pathway mutated, resectable gallbladder cancer: study protocol for a ctDNA-based, multicentre, open-label, randomised, controlled, phase II trial

INTRODUCTION: Gallbladder cancer (GBC) is an aggressive type of digestive system cancer with a dismal outcome. Given the lack of effective treatment options, the disease rapidly reoccurs and 5-year survival rate is <5%. Our team previously found that a significant percentage of GBC tissues harbou...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Mao, Zhao, Yuhao, Li, Yongsheng, Cui, Xuya, Liu, Fatao, Wu, Wenguang, Wang, Xu-An, Li, Maolan, Liu, Yun, Liu, Yingbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980349/
https://www.ncbi.nlm.nih.gov/pubmed/36854604
http://dx.doi.org/10.1136/bmjopen-2022-061892

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980349/
https://www.ncbi.nlm.nih.gov/pubmed/36854604
http://dx.doi.org/10.1136/bmjopen-2022-061892

Ejemplares similares